Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;54(2):412-416.
doi: 10.1638/2022-0095.

DIAGNOSIS AND TREATMENT OF A NATURAL INFECTION WITH TRYPANOSOMA CRUZI (CHAGAS DISEASE) IN A SYMPTOMATIC DE BRAZZA'S MONKEY (CERCOPITHECUS NEGLECTUS) IN ALABAMA

Stephanie McCain  1 , Richard R Sim  2 , Bridget Weidner  2 , Anne E Rivas  2 , Brooke White  3 , Lisa D Auckland  4 , Rick L Tarleton  3 , Sarah Hamer  4
Affiliations

DIAGNOSIS AND TREATMENT OF A NATURAL INFECTION WITH TRYPANOSOMA CRUZI (CHAGAS DISEASE) IN A SYMPTOMATIC DE BRAZZA'S MONKEY (CERCOPITHECUS NEGLECTUS) IN ALABAMA

Stephanie McCain et al. J Zoo Wildl Med. 2023 Jul.

Abstract

Trypanosoma cruzi, the causative agent of Chagas disease, is a zoonotic, vector-borne, protozoan hemoflagellate with a wide host range. An 11-yr-old, captive-bred male De Brazza's monkey (Cercopithecus neglecus) presented with weight loss despite normal appetite. Examination revealed hypoglycemia, nonregenerative anemia, and many trypanosomes on a blood smear. A whole blood sample was PCR-positive for T. cruzi discrete typing unit TcIV and the monkey seroconverted using two different methods. The monkey was treated with the standard human dose of benznidazole twice daily for 60 d; however, blood obtained over the next 1.5 yr posttreatment remained PCR-positive for T. cruzi. A second course of benznidazole at a higher dose but lower frequency for 26 wk was required for the monkey to convert to sustained PCR-negative status. The monkey recovered with no apparent lasting effects.

PubMed Disclaimer

References

    1. Aras R, Bastos C, Mota G, Sodré F, Moreira A, Tavares A, Lima JC. Troponin in Chagas disease. Braz J Infect Dis. 2013;7(6):358–359. - PubMed
    1. Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas’ disease in the United States. Clin Microbiol Rev. 2011;24(4):655–681. - PMC - PubMed
    1. Brown EL, Roellig DM, Gompper ME, Monell RJ, Wenning KM, Gabriel MW, Yabsley MJ. Seroprevalence of Trypanosoma cruzi among eleven potential reservoir species from six states across the southern United States. Vector Borne Zoonotic Dis. 2010;10(8): 757–763. - PMC - PubMed
    1. Bustamante JM, Sanchez-Valdez F, Padilla AM, White B, Wang W, Tarleton RL. A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease. Sci Transl Med. 2020; 10.1126/scitranslmed.abb7656 - DOI - PMC - PubMed
    1. Cura CI, Duffy T, Lucero RH, Bisio M, Péneau J, Jimenez-Coello M, Calabuig E, Gimenez MJ, Valencia Ayala E, Kjos SA, Santalla J. Multiplex real-time PCR assay using TaqMan probes for the identification of Trypanosoma cruzi DTUs in biological and clinical samples. PLoS Neglected Tropic Dis. [Internet]. 2015. Available from doi:10.1371/journal.pntd.0003765 - DOI - PMC - PubMed

LinkOut - more resources